Can I Take Glycine with Egrifta (Tesamorelin)?

What Is Tesamorelin and Why Does the GH Axis Matter Here?

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). Injected subcutaneously once daily at 2 mg, it binds pituitary GHRH receptors and drives a pulsatile increase in GH secretion, which subsequently raises insulin-like growth factor 1 (IGF-1) and shifts adipose metabolism away from visceral fat accumulation. The FDA approved it specifically for HIV-associated lipodystrophy after the phase III EGRIFTA trial (N=412) showed a statistically significant 18% reduction in visceral adipose tissue area at 26 weeks versus placebo (P<0.001) [1].

Because tesamorelin works by amplifying the GH axis, anything else that also stimulates GH secretion deserves scrutiny. GH raises fasting glucose through counter-regulatory mechanisms, and the prescribing information for Egrifta SV already lists glucose intolerance and new-onset diabetes as recognized adverse effects [2].

How Tesamorelin Raises IGF-1

After a single 2 mg dose, mean IGF-1 standard deviation scores (SDS) rise significantly within two weeks and plateau around 0.5 to 1.0 SDS above baseline in most patients [1]. Sustained IGF-1 elevation is what drives visceral fat reduction but also what modestly impairs peripheral insulin sensitivity.

The Glucose Concern in Practice

In the phase III trial, diabetes or impaired glucose tolerance occurred in 4.3% of tesamorelin patients versus 1.5% of placebo patients at 26 weeks [1]. Patients who already have diabetes or prediabetes are at the highest risk of clinically meaningful glucose worsening.

What Is Glycine and What Does It Do to Growth Hormone?

Glycine is the simplest amino acid. The body synthesizes it endogenously, and it is present in collagen-rich foods. As a supplement, it is sold in 3 to 5 g doses and marketed primarily for sleep quality, joint support, and skin collagen production. Glycine crosses the blood-brain barrier and acts as an inhibitory neurotransmitter at glycine receptors in the brainstem and spinal cord [3].

Glycine's Direct Effect on GH Secretion

This is the part most patients and some clinicians miss. A double-blind crossover study (N=19 healthy adults) published in the journal Psychiatry and Clinical Neurosciences found that 3 g of oral glycine before sleep significantly increased slow-wave sleep and raised overnight GH pulse amplitude compared to placebo [4]. Slow-wave (stage N3) sleep is the dominant physiological window for GH secretion; deepening that sleep stage is a legitimate, if modest, GH secretagogue effect.

A separate study of 10 male subjects given 6.75 g glycine orally found a measurable rise in serum GH peaking at 2 to 3 hours post-ingestion [5]. The mechanism appears to involve glycine's role as a precursor to creatine and glutathione as well as direct stimulation of GHRH neurons in the hypothalamus.

The clinical takeaway: glycine is not simply a passive amino acid supplement. It has a documented GH-stimulating effect, which is pharmacodynamically additive to tesamorelin's mechanism.

Glycine and Insulin Sensitivity: A Mixed Picture

Glycine's glycemic effects are complicated. Epidemiologically, lower plasma glycine levels correlate with higher risk of type 2 diabetes [6]. In a randomized trial (N=60), glycine supplementation at 5 g per day for three months improved fasting glucose and HOMA-IR in patients with metabolic syndrome [7]. That finding is directionally opposite to tesamorelin's tendency to worsen insulin sensitivity. Whether glycine's insulin-sensitizing effect would blunt tesamorelin's glucose-raising effect in clinical practice is unknown. No trial has tested this directly.

Is This Interaction Pharmacokinetic or Pharmacodynamic?

Short answer: pharmacodynamic. Tesamorelin is a 44-amino-acid peptide administered subcutaneously. It is cleaved by serum and tissue peptidases; it does not undergo hepatic CYP450 metabolism [2]. Glycine is a small amino acid absorbed in the gut via sodium-coupled transporters. The two compounds do not share metabolic enzymes, plasma protein binding sites, or renal excretion pathways. Classical pharmacokinetic interactions (absorption, distribution, metabolism, excretion) are not expected.

The interaction concern is entirely at the level of effect: both compounds increase GH output through different mechanisms, and combining them may produce a larger combined GH signal than either alone.

Why "Pharmacodynamic" Still Matters Clinically

Pharmacodynamic interactions are often under-appreciated because they do not show up on standard drug interaction databases built around CYP enzyme substrates. Lexicomp and Drugs.com, for example, list no formal interaction between tesamorelin and glycine. That absence reflects a data gap, not a safety guarantee. The FDA label for Egrifta SV specifically warns prescribers to monitor "patients with diabetes or at risk for diabetes" and to adjust anti-diabetic therapy accordingly [2].

What the Natural Medicines Database Says

The Natural Medicines Comprehensive Database (Therapeutic Research Center) rates the tesamorelin-glycine combination as having "insufficient reliable evidence to rate" for interaction severity. That rating acknowledges the biological plausibility of additive GH stimulation without elevating it to a formal contraindication.

Practical Risk Assessment: Who Is Most Affected?

Not every patient on tesamorelin faces the same risk from adding glycine. Risk stratification should consider at least four factors.

Baseline Glycemic Status

Patients with a hemoglobin A1c (HbA1c) at or above 5.7% (prediabetes threshold per ADA criteria) carry the most meaningful risk [8]. Tesamorelin already nudges glucose upward; an additive GH pulse from glycine could push a borderline patient into clinical glucose intolerance requiring medication adjustment.

Glycine Dose

A 3 g bedtime dose for sleep is the most common OTC regimen. Doses below 3 g appear to have a smaller effect on overnight GH pulses, while doses above 5 g have limited additional sleep data and are rarely studied in combination with GH-axis drugs. Staying at or below 3 g is a reasonable harm-reduction boundary if a prescriber decides co-administration is acceptable.

Timing Relative to Tesamorelin Injection

Tesamorelin's peak GH stimulation occurs within 1 to 2 hours of subcutaneous injection. If glycine is taken at bedtime and tesamorelin is injected at bedtime as well, the GH pulses may overlap. Separating the tesamorelin injection to morning and reserving glycine for bedtime reduces the window of concurrent peak GH stimulation, though it does not eliminate the cumulative 24-hour GH load.

Existing IGF-1 Level

Patients whose IGF-1 SDS is already in the upper-normal or above-normal range on tesamorelin monotherapy are less ideal candidates for adding a GH secretagogue. IGF-1 above 2 SDS has been associated with an increased risk of colon polyp formation in acromegaly literature, though tesamorelin rarely drives IGF-1 that high [9].

Collagen Synthesis: The Third Dimension

Both tesamorelin and glycine influence collagen. GH and IGF-1 upregulate type I and type III collagen synthesis in dermal fibroblasts and connective tissue [10]. Glycine provides approximately one-third of collagen's amino acid composition by mole fraction and is rate-limiting for collagen biosynthesis when dietary intake is low [11].

Theoretically, combining them might produce a greater collagen synthesis effect. For most patients, this is not a harm. People taking these agents for joint support or skin quality may see this as a benefit. The concern is narrow: patients with conditions where excessive fibrotic tissue formation is undesirable (such as certain inflammatory myopathies) should discuss the combination with their rheumatologist or internist.

Sleep Quality: A Potential Benefit Worth Monitoring

Glycine's most evidence-backed application is improving subjective sleep quality. A randomized, placebo-controlled trial published in Sleep and Biological Rhythms (N=11, crossover design) found that 3 g glycine at bedtime reduced fatigue and improved daytime alertness the following morning [12]. A second trial (N=15) replicated the reduction in sleep onset latency [13].

Patients on tesamorelin often have HIV-related comorbidities including sleep disturbance. If a prescriber decides the glycine-tesamorelin combination is acceptable from a metabolic standpoint, the sleep benefit may represent a genuine quality-of-life gain for this population. The GH-axis amplification that comes with improved slow-wave sleep is the trade-off to weigh.

The HealthRX Decision Framework: Should You Take Glycine with Tesamorelin?

The following four-step framework is designed for discussion with your prescribing clinician, not as a substitute for it.

Step 1: Establish Metabolic Baseline Before Starting Glycine

Order or review: fasting glucose, HbA1c, and IGF-1 SDS. If HbA1c is above 6.4% (diabetes threshold per ADA 2024 Standards of Care), glycine should not be added without close endocrinology input [8]. If HbA1c is between 5.7% and 6.4%, proceed with heightened monitoring rather than automatic exclusion.

Step 2: Choose a Conservative Glycine Dose

Start at 2 to 3 g at bedtime. Do not exceed 5 g daily without medical supervision. Lower doses produce the sleep benefit with a smaller GH-stimulating signal.

Step 3: Separate Peak GH Windows Where Possible

If your tesamorelin injection is currently at bedtime, discuss shifting it to morning administration with your prescriber. Both morning and evening injection timing are used clinically; the prescribing information does not mandate a specific time of day [2]. A morning injection followed by bedtime glycine places the two peak GH windows approximately 12 to 16 hours apart.

Step 4: Recheck Glucose and IGF-1 at 8 Weeks

A fasting glucose check at 4 to 8 weeks after adding glycine is a reasonable safeguard. If fasting glucose has risen by more than 10 mg/dL above baseline or IGF-1 SDS has exceeded 2.0, discuss reducing or stopping glycine.

What to Tell Your Prescriber

Patients sometimes worry that mentioning supplements will be dismissed. Frame the conversation around the GH-axis effect, not just "I'm taking a supplement." A specific opening: "I'm considering glycine at 3 g at bedtime for sleep. I understand it has a mild GH-stimulating effect and I wanted to review my recent IGF-1 and glucose before starting." The American Association of Clinical Endocrinologists (AACE) 2023 growth hormone guidelines recommend that prescribers document all GH-axis-active agents, including nutritional supplements, in patients on GH-pathway therapy [14].

As the Egrifta SV prescribing information states directly: "Patients with active malignancy should not be treated with tesamorelin. Patients with diabetes mellitus should be monitored for changes in glucose tolerance when treated with tesamorelin" [2]. Adding a GH secretagogue to the regimen makes that monitoring instruction more, not less, relevant.

Monitoring Schedule for Patients Taking Both Agents

| Measurement | Baseline | 4 to 8 Weeks Post-Glycine Start | Every 6 Months | |---|---|---|---| | Fasting glucose (mg/dL) | Yes | Yes | Yes | | HbA1c (%) | Yes | No | Yes | | IGF-1 SDS | Yes | Optional | Yes | | Subjective sleep score | Optional | Yes | Optional |

Special Populations

Patients with Pre-existing Diabetes on Anti-diabetic Medication

Metformin or GLP-1 receptor agonists do not interact pharmacokinetically with either tesamorelin or glycine. However, if glycine-augmented GH secretion worsens insulin resistance, anti-diabetic drug doses may need upward adjustment. Monitor fasting glucose weekly for the first month in this group.

Patients Over 60

Endogenous GH secretion declines with age. Older patients on tesamorelin may actually tolerate additive GH stimulation from glycine with less risk of IGF-1 overshoot, because their baseline GH secretory capacity is lower. This does not remove the need for glucose monitoring but contextualizes the risk.

Patients Also Taking Sermorelin or Ipamorelin

Some patients use tesamorelin alongside other peptides prescribed off-label, such as sermorelin or ipamorelin/CJC-1295. Adding glycine on top of stacked GH secretagogues compounds the GH amplification meaningfully. Glycine should generally be avoided in this scenario without detailed endocrinology oversight.

What the Evidence Does Not Yet Tell Us

No randomized controlled trial has enrolled patients on tesamorelin and randomized them to glycine versus placebo. The interaction risk described throughout this article is built on: the known mechanism of tesamorelin [1,2], the documented GH-stimulating effect of glycine in healthy adults [4,5], and the established pharmacodynamic principle that additive stimulation of a shared effector (pituitary GH release) carries proportionate risk of that effector's adverse effects (glucose elevation, IGF-1 overshoot).

That mechanistic reasoning is well-grounded, but it is not a substitute for direct trial data. Patients should weigh the sleep and potential metabolic benefits of glycine against a theoretical, not proven, risk of glucose worsening. Most patients with well-controlled baseline glucose will likely tolerate 3 g glycine at bedtime without a clinically detectable change in glycemic control. The patients who cannot afford that uncertainty are those already at the edge of diabetes thresholds.